<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is an <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> defined by the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> in plasma of patients with vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> and/or pregnancy morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>APS is considered the major cause of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> in young adults and is a generally accepted cause of recurrent pregnancy loss </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of autoantibodies strongly related to the clinical manifestations of APS and with a widely recognized pathogenic role in <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In this article, recent clinical and pathophysiological advances in APS are discussed </plain></SENT>
</text></document>